NuProbe, a genomics and molecular diagnostics company specialized in ultrasensitive sequencing panels, announced the closing of its oversubscribed $42M fundraising. The lead investors for this financing round are BioTrack Capital and Yonghua Capital.

Taifu Capital, Panlin Capital, Juming Capital, and Tuobang Capital also participated in the investment. BMD China served as financial advisors for this financing round. Additionally, NuProbe's previous investors Sequoia Capital China, Ruomu Capital, and Serica Partners also co-invested in the deal.

NuProbe is a genomics and molecular diagnostics company with molecular diagnostic technologies to improve the sensitivity of sequencing mutations and copy number variations by over 10-fold. NuProbe's vision is to offer affordable, timely, and accurate disease state information to enable precision medicine and improve patient outcomes.